U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H32N2O2.2ClH
Molecular Weight 393.391
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CAMYLOFIN HYDROCHLORIDE

SMILES

Cl.Cl.CCN(CC)CCNC(C(=O)OCCC(C)C)C1=CC=CC=C1

InChI

InChIKey=ZHRVNCCPAKIGRH-UHFFFAOYSA-N
InChI=1S/C19H32N2O2.2ClH/c1-5-21(6-2)14-13-20-18(17-10-8-7-9-11-17)19(22)23-15-12-16(3)4;;/h7-11,16,18,20H,5-6,12-15H2,1-4H3;2*1H

HIDE SMILES / InChI

Molecular Formula C19H32N2O2
Molecular Weight 320.4696
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.ijrcog.org/index.php/ijrcog/article/view/1419

Camylofin is an antimuscarinic. This medication is used as antispasmodic in biliary colic, renal and ureteric colic, dysmenorrhoea, peptic ulcer and chronic enterocolitis. It is used to treat stomach ache in infants and children. Camylofin should be the first choice and may be preferred over other drugs for cervical dilatation and acceleration of active phase of labor.

Originator

Curator's Comment: refernce retrieved from https://www.ncbi.nlm.nih.gov/pubmed/13331655

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ANAFORTAN

Approved Use

Camylofin is used as an anti-spasmodic. Camylofin is primarily indicated in conditions like Angina, Biliary colic, Dysmenorrhoea, Migraine, Myocardial infarction, Pancreatitis, Renal colic, Spasticity.
Primary
ANAFORTAN

Approved Use

Camylofin is used as an anti-spasmodic. Camylofin is primarily indicated in conditions like Angina, Biliary colic, Dysmenorrhoea, Migraine, Myocardial infarction, Pancreatitis, Renal colic, Spasticity.
Doses

Doses

DosePopulationAdverse events​
120 mg single, intramuscular
Higher than recommended
Dose: 120 mg
Route: intramuscular
Route: single
Dose: 120 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
Other AEs: Skin rash, Tachycardia...
Other AEs:
Skin rash (18.8%)
Tachycardia (12.5%)
Drowsiness (6.25%)
Facial flushing (6.25%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Tachycardia 12.5%
120 mg single, intramuscular
Higher than recommended
Dose: 120 mg
Route: intramuscular
Route: single
Dose: 120 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
Skin rash 18.8%
120 mg single, intramuscular
Higher than recommended
Dose: 120 mg
Route: intramuscular
Route: single
Dose: 120 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
Drowsiness 6.25%
120 mg single, intramuscular
Higher than recommended
Dose: 120 mg
Route: intramuscular
Route: single
Dose: 120 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
Facial flushing 6.25%
120 mg single, intramuscular
Higher than recommended
Dose: 120 mg
Route: intramuscular
Route: single
Dose: 120 mg
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Antispasmodics for labour.
2012-08-15
Development and characterization of colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride for the treatment of ulcerative colitis.
2010-09
Determination of the analgesic components of Spasmomigraine tablet by liquid chromatography with ultraviolet detection.
2007-03-22
A study of metabolism of isoamyl alpha-[N-(beta-diethylamino-ethyl)]-aminophenylacetate (avacan).
1956-03
[Pharmacology of Avacan].
1951-04-06
Patents

Sample Use Guides

0.285 to 0.857 mg/kg to be taken every 8 hrs.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:59:47 GMT 2025
Edited
by admin
on Mon Mar 31 17:59:47 GMT 2025
Record UNII
MO02H82C7M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CAMYLOFIN HYDROCHLORIDE
MART.   WHO-DD  
Common Name English
ACAMYLOPHENINE HYDROCHLORIDE
JAN  
Preferred Name English
CAMYLOFINE DIHYDROCHLORIDE [MI]
Common Name English
ISOPENTYL 2-(2-DIETHYLAMINOETHYLAMINO)-2-PHENYLACETATE DIHYDROCHLORIDE
Systematic Name English
CAMYLOFIN HCL
Common Name English
ACAMYLOPHENINE HYDROCHLORIDE [JAN]
Common Name English
Camylofin hydrochloride [WHO-DD]
Common Name English
CAMYLOFIN HYDROCHLORIDE [MART.]
Common Name English
NSC-759249
Code English
CAMYLOPHENINE DIHYDROCHLORIDE
Common Name English
CAMYLOFINE HYDROCHLORIDE
Common Name English
Code System Code Type Description
MESH
C004644
Created by admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
PRIMARY
ECHA (EC/EINECS)
227-571-0
Created by admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
PRIMARY
RXCUI
236175
Created by admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
PRIMARY RxNorm
NSC
759249
Created by admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
PRIMARY
PUBCHEM
22182
Created by admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
PRIMARY
CAS
5892-41-1
Created by admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
PRIMARY
ChEMBL
CHEMBL253592
Created by admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
PRIMARY
MERCK INDEX
m99
Created by admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID70974421
Created by admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
PRIMARY
SMS_ID
100000084848
Created by admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
PRIMARY
EVMPD
SUB01018MIG
Created by admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
PRIMARY
FDA UNII
MO02H82C7M
Created by admin on Mon Mar 31 17:59:47 GMT 2025 , Edited by admin on Mon Mar 31 17:59:47 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY